Allogene Therapeutics (ALLO) Earnings Date, Estimates & Call Transcripts → Biggest hedge fund manager has huge warning for U.S. dollar (From Stansberry Research) (Ad) Free allo Stock Alerts $2.75 -0.11 (-3.85%) (As of 02:40 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 13After Market ClosesConfirmedActual EPS (Mar. 14) -$0.43 Beat By $0.04 Consensus EPS (Mar. 14) -$0.47 Get Allogene Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for ALLO and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueALLO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALLO Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchBiggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."Get the details before it's taken offline. Allogene Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($0.58)($0.44)($0.51)Q2 20244($0.58)($0.46)($0.52)Q3 20244($0.59)($0.48)($0.53)Q4 20244($0.59)($0.50)($0.54)FY 202416($2.34)($1.88)($2.08)Q1 20251($0.50)($0.50)($0.50)Q2 20251($0.51)($0.51)($0.51)Q3 20251($0.50)($0.50)($0.50)Q4 20251($0.51)($0.51)($0.51)FY 20254($2.02)($2.02)($2.02)ALLO Earnings Date and InformationAllogene Therapeutics last issued its quarterly earnings results on March 14th, 2024. The reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.04. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.05 million. Allogene Therapeutics has generated ($2.09) earnings per share over the last year (($2.09) diluted earnings per share). Earnings for Allogene Therapeutics are expected to remain at ($1.69) per share in the coming year. Allogene Therapeutics has confirmed that its next quarterly earnings report will be published on Monday, May 13th, 2024. Allogene Therapeutics will be holding an earnings conference call on Monday, May 13th at 5:00 PM Eastern. Interested parties can register for or listen to the call.. Read More Allogene Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/13/2024Confirmed)------- 3/14/2024Q4 2023($0.47)($0.43)+$0.04($0.35)$0.05 million$0.02 million11/2/2023Q3 2023($0.53)($0.37)+$0.16($0.37)$0.05 million$0.04 million8/2/2023Q2 2023($0.59)($0.53)+$0.06($0.53)$0.01 million$0.04 million 5/3/2023Q1 2023($0.63)($0.68)($0.05)($0.68)$0.08 million$0.05 million 2/28/2023Q4 2022($0.71)($0.66)+$0.05($0.66)$0.06 million$0.05 million 11/2/2022Q3 2022($0.62)($0.58)+$0.04($0.58)$0.01 million$0.05 million Get the Latest News and Ratings for ALLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/9/2022Q2 2022($0.61)($0.52)+$0.09($0.52)$0.08 million$0.09 million 5/4/2022Q1 2022($0.59)($0.56)+$0.03($0.56)$0.10 million$0.06 million 2/23/2022Q4 2021($0.61)($0.54)+$0.07($0.54)-$0.05 million 11/4/2021Q3 2021($0.56)($0.57)($0.01)($0.57)-$0.05 million 8/3/2021Q2 2021($0.55)($0.53)+$0.02($0.53)$0.95 million$0.04 million Allogene Therapeutics Earnings - Frequently Asked Questions When is Allogene Therapeutics's earnings date? Allogene Therapeutics has confirmed that its next quarterly earnings data will be published on Monday, May 13th, 2024. Learn more on ALLO's earnings history. Did Allogene Therapeutics beat their earnings estimates last quarter? In the previous quarter, Allogene Therapeutics (NASDAQ:ALLO) reported ($0.43) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.47) by $0.04. Learn more on analysts' earnings estimate vs. ALLO's actual earnings. How much revenue does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded annual revenue of $95,000.00. How much profit does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded net income of -$327.27 million. ALLO has generated -$2.09 earnings per share over the last four quarters. What is Allogene Therapeutics's EPS forecast for next year? Allogene Therapeutics's earnings are expected to stay at ($1.69) per share in the next year. More Earnings Resources from MarketBeat Related Companies: ProKidney Earnings Results Humacyte Earnings Results Taysha Gene Therapies Earnings Results Alector Earnings Results Fate Therapeutics Earnings Results Cabaletta Bio Earnings Results C4 Therapeutics Earnings Results Editas Medicine Earnings Results Voyager Therapeutics Earnings Results Valneva Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:ALLO) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
